Atherosclerosis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：310頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Atherosclerosis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Atherosclerosis - Pipeline Review, H1 2014’, provides an overview of the Atherosclerosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Atherosclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atherosclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Atherosclerosis - Pipeline Review, H1 2014’, provides an overview of the Atherosclerosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Atherosclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atherosclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Atherosclerosis Overview 12
Therapeutics Development 13
Pipeline Products for Atherosclerosis - Overview 13
Pipeline Products for Atherosclerosis - Comparative Analysis 14
Atherosclerosis - Therapeutics under Development by Companies 15
Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 21
Atherosclerosis - Pipeline Products Glance 24
Late Stage Products 24
Clinical Stage Products 25
Early Stage Products 26
Unknown Stage Products 27
Atherosclerosis - Products under Development by Companies 28
Atherosclerosis - Products under Investigation by Universities/Institutes 34
Atherosclerosis - Companies Involved in Therapeutics Development 36
Bristol-Myers Squibb Company 36
Aastrom Biosciences, Inc. 37
Johnson & Johnson 38
Boehringer Ingelheim GmbH 39
F. Hoffmann-La Roche Ltd. 40
AstraZeneca PLC 41
Eli Lilly and Company 42
GlaxoSmithKline plc 43
MedImmune, LLC 44
Isis Pharmaceuticals, Inc. 45
Daiichi Sankyo Company, Limited 46
Merck & Co., Inc. 47
Novartis AG 48
Dr. Reddy's Laboratories Limited 49
Kowa Company, Ltd. 50
The Medicines Company 51
Zydus Cadila Healthcare Limited 52
Bayer AG 53
OPKO Health, Inc. 54
Genfit SA 55
CSL Limited 56
Yuhan Corporation 57
Anagen Therapeutics, Inc. 58
Cytos Biotechnology AG 59
Resverlogix Corp. 60
Galapagos NV 61
Pronova BioPharma ASA 62
AFFiRiS AG 63
CIMAB S.A. 64
Jenrin Discovery, Inc. 65
Phenex Pharmaceuticals AG 66
Spherix Incorporated 67
Arisaph Pharmaceuticals, Inc. 68
Funxional Therapeutics Ltd 69
GenKyoTex S.A. 70
Vascular Biogenics Ltd. 71
Cardax Pharmaceuticals, Inc. 72
KineMed, Inc. 73
Bridge Bioresearch Plc 74
ChemoCentryx, Inc. 75
Provid Pharmaceuticals, Inc. 76
Vitae Pharmaceuticals, Inc. 77
Athera Biotechnologies AB 78
NasVax Ltd. 79
Regulus Therapeutics Inc. 80
Janssen Biotech, Inc. 81
Esperion Therapeutics, Inc. 82
Vascular Pharmaceuticals, Inc. 83
SelectX Pharmaceuticals, Inc. 84
InVasc Therapeutics, Inc. 85
Otsuka Holdings Co., Ltd. 86
DoNatur GmbH 87
Artery Therapeutics, Inc. 88
Lead Discovery Center GmbH 89
AtheroNova Inc. 90
Dybly AG 91
vida therapeutics inc. 92
Biospherics.net Incorporated 93
Dong-A Socio Holdings Co Ltd 94
Atherosclerosis - Therapeutics Assessment 95
Assessment by Monotherapy Products 95
Assessment by Combination Products 96
Assessment by Target 97
Assessment by Mechanism of Action 102
Assessment by Route of Administration 107
Assessment by Molecule Type 109
Drug Profiles 112
anacetrapib - Drug Profile 112
vorapaxar sulfate - Drug Profile 114
aliskiren fumarate - Drug Profile 116
evacetrapib - Drug Profile 118
DRL-17822 - Drug Profile 120
VB-201 - Drug Profile 121
RVX-208 - Drug Profile 123
CSL-112 - Drug Profile 125
chloroquine - Drug Profile 126
SYN-20110119RU - Drug Profile 127
XL-652 - Drug Profile 128
darapladib - Drug Profile 130
MDCO-216 - Drug Profile 132
ATH-03 - Drug Profile 134
AHRO-001 - Drug Profile 135
ISIS-APOARx - Drug Profile 137
(aspirin + clopidogrel) - Drug Profile 138
ACP-501 - Drug Profile 139
Vaccine for Atherosclerosis - Drug Profile 141
CVX-210H - Drug Profile 142
BI-691751 - Drug Profile 143
RO-6836191 - Drug Profile 144
LPC-01 - Drug Profile 145
Artpep-2 - Drug Profile 146
FX-141-L - Drug Profile 147
FX-87-L - Drug Profile 148
SOL-02 - Drug Profile 149
ixmyelocel-T - Drug Profile 150
SPX-7233801 - Drug Profile 153
ARI-1778 - Drug Profile 154
K-877 - Drug Profile 155
JD-2000 Series - Drug Profile 156
JD-5000 Series - Drug Profile 157
JD-6000 Series - Drug Profile 158
CYT018-IL1aQb - Drug Profile 159
AT-5261 - Drug Profile 160
GKT-137831 - Drug Profile 161
CDX-085 - Drug Profile 162
INV-404 - Drug Profile 164
INV-405 - Drug Profile 165
Drug For Atherosclerotic Plaque - Drug Profile 166
Annexin A-5 - Drug Profile 167
PC-mAb - Drug Profile 168
Anti-CD3 Oral Immunotherapy - Drug Profile 170
Protein-Based HDL Therapies - Drug Profile 172
Anti microRNA-33a/b - Drug Profile 174
(SPX-106 + D-tagatose) - Drug Profile 175
CD14 Project - Drug Profile 177
PRC-4016 - Drug Profile 178
Drug For Atherosclerosis - Drug Profile 179
YH_Chem3 - Drug Profile 180
KM-011 - Drug Profile 181
COR-2 - Drug Profile 182
CideB Antisense Oligonucleotide - Drug Profile 183
CCX-872 - Drug Profile 184
MCS-18 - Drug Profile 185
AEM-28 - Drug Profile 187
KRP-206 - Drug Profile 188
CCX-771 - Drug Profile 189
ketanserin - Drug Profile 190
Progranulin - Drug Profile 191
ARA-290 - Drug Profile 192
VTP-4 - Drug Profile 194
microRNA-145 Gene Therapy - Drug Profile 195
VPI-2690-B - Drug Profile 196
FX-5A - Drug Profile 197
Cell Migration Inhibitors - Drug Profile 198
ATI-829 - Drug Profile 199
GKT-136901 - Drug Profile 200
melittin - Drug Profile 202
GQ-16 - Drug Profile 203
BAY-606583 - Drug Profile 204
3-Hydroxyanthranilic Acid - Drug Profile 205
Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 206
VPI-2690-B - Drug Profile 207
Next Generation Lecinoxoids - Drug Profile 208
Bone Morphogenic Protein Inhibitors - Drug Profile 209
cSN-50 - Drug Profile 210
Atheroprotective Vaccine - Drug Profile 212
Small Molecules to Inhibit Chymase for Atherosclerosis - Drug Profile 213
DS-1442 - Drug Profile 214
Anti-CD20 Monoclonal Antibody - Drug Profile 215
RNAi Oligonucleotide to Inhibit STIM1 Cardiovascular Disorders - Drug Profile 216
DYB-186 - Drug Profile 217
Adenoviral Vector Based Human ABCG1 Gene Therapy - Drug Profile 218
AZ-876 - Drug Profile 219
Peptides Inhibiting Calcineurin - Drug Profile 220
Anti-CD97 Antibodies - Drug Profile 221
Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation - Drug Profile 222
Anti Idiotype chP3R99Q Vaccine - Drug Profile 223
AHRO-003 - Drug Profile 224
rPAI-123 - Drug Profile 225
BSN-723 - Drug Profile 226
BSN-272 - Drug Profile 227
K-312 - Drug Profile 228
D-4F - Drug Profile 229
EP-80317 - Drug Profile 230
Small Molecule to Inhibit CD40-TRAF6 Interaction for Atherosclerosis - Drug Profile 231
Biglycan Therapy - Drug Profile 232
PX-20606 - Drug Profile 233
CSN-501 - Drug Profile 234
CB-102 - Drug Profile 235
HDL AuNPs for Atherosclerosis and Lymphoma - Drug Profile 236
Lipase Inhibitors - Drug Profile 238
Small Molecules For Cardiovascular Disease - Drug Profile 239
Drug for Atherosclerosis - Drug Profile 240
Small Molecules for Atherosclerosis and Metabolic Diseases - Drug Profile 241
Drug Targeting F11R - Drug Profile 242
Stem Cell Therapy For Atherosclerosis - Drug Profile 244
Tanshinone IIA - Drug Profile 245
S-Allymercapto-N-Acetylcysteine - Drug Profile 246
Hepcidin Inhibitors - Drug Profile 247
Atherosclerosis Program - Drug Profile 248
Drug For Chronic Inflammatory Diseases - Drug Profile 249
Cannabinoid Receptor 2 Agonist - Drug Profile 250
Small Molecules to Inhibit Lipoxygenase for Oncology, Cardiovascular and Respiratory Disorders - Drug Profile 251
D-Amlexanox - Drug Profile 252
INV-88 - Drug Profile 253
dicumarol - Drug Profile 254
Nanotherapeutics - Drug Profile 255
AHRO-002 - Drug Profile 256
Atherosclerosis - Recent Pipeline Updates 257
Atherosclerosis - Dormant Projects 286
Atherosclerosis - Discontinued Products 291
Atherosclerosis - Product Development Milestones 292
Featured News & Press Releases 292
Appendix 301
Methodology 301
Coverage 301
Secondary Research 301
Primary Research 301
Expert Panel Validation 301
Contact Us 302
Disclaimer 302
List of Tables
Number of Products under Development for Atherosclerosis, H1 2014 21
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2014 22
Number of Products under Development by Companies, H1 2014 24
Number of Products under Development by Companies, H1 2014 (Contd..1) 25
Number of Products under Development by Companies, H1 2014 (Contd..2) 26
Number of Products under Development by Companies, H1 2014 (Contd..3) 27
Number of Products under Development by Companies, H1 2014 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H1 2014 30
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 31
Comparative Analysis by Late Stage Development, H1 2014 32
Comparative Analysis by Clinical Stage Development, H1 2014 33
Comparative Analysis by Early Stage Development, H1 2014 34
Comparative Analysis by Unknown Stage Development, H1 2014 35
Products under Development by Companies, H1 2014 36
Products under Development by Companies, H1 2014 (Contd..1) 37
Products under Development by Companies, H1 2014 (Contd..2) 38
Products under Development by Companies, H1 2014 (Contd..3) 39
Products under Development by Companies, H1 2014 (Contd..4) 40
Products under Development by Companies, H1 2014 (Contd..5) 41
Products under Investigation by Universities/Institutes, H1 2014 42
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 43
Atherosclerosis - Pipeline by Bristol-Myers Squibb Company, H1 2014 44
Atherosclerosis - Pipeline by Aastrom Biosciences, Inc., H1 2014 45
Atherosclerosis - Pipeline by Johnson & Johnson, H1 2014 46
Atherosclerosis - Pipeline by Boehringer Ingelheim GmbH, H1 2014 47
Atherosclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 48
Atherosclerosis - Pipeline by AstraZeneca PLC, H1 2014 49
Atherosclerosis - Pipeline by Eli Lilly and Company, H1 2014 50
Atherosclerosis - Pipeline by GlaxoSmithKline plc, H1 2014 51
Atherosclerosis - Pipeline by MedImmune, LLC, H1 2014 52
Atherosclerosis - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 53
Atherosclerosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 54
Atherosclerosis - Pipeline by Merck & Co., Inc., H1 2014 55
Atherosclerosis - Pipeline by Novartis AG, H1 2014 56
Atherosclerosis - Pipeline by Dr. Reddy's Laboratories Limited, H1 2014 57
Atherosclerosis - Pipeline by Kowa Company, Ltd., H1 2014 58
Atherosclerosis - Pipeline by The Medicines Company, H1 2014 59
Atherosclerosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 60
Atherosclerosis - Pipeline by Bayer AG, H1 2014 61
Atherosclerosis - Pipeline by OPKO Health, Inc., H1 2014 62
Atherosclerosis - Pipeline by Genfit SA, H1 2014 63
Atherosclerosis - Pipeline by CSL Limited, H1 2014 64
Atherosclerosis - Pipeline by Yuhan Corporation, H1 2014 65
Atherosclerosis - Pipeline by Anagen Therapeutics, Inc., H1 2014 66
Atherosclerosis - Pipeline by Cytos Biotechnology AG, H1 2014 67
Atherosclerosis - Pipeline by Resverlogix Corp., H1 2014 68
Atherosclerosis - Pipeline by Galapagos NV, H1 2014 69
Atherosclerosis - Pipeline by Pronova BioPharma ASA, H1 2014 70
Atherosclerosis - Pipeline by AFFiRiS AG, H1 2014 71
Atherosclerosis - Pipeline by CIMAB S.A., H1 2014 72
Atherosclerosis - Pipeline by Jenrin Discovery, Inc., H1 2014 73
Atherosclerosis - Pipeline by Phenex Pharmaceuticals AG, H1 2014 74
Atherosclerosis - Pipeline by Spherix Incorporated, H1 2014 75
Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2014 76
Atherosclerosis - Pipeline by Funxional Therapeutics Ltd, H1 2014 77
Atherosclerosis - Pipeline by GenKyoTex S.A., H1 2014 78
Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H1 2014 79
Atherosclerosis - Pipeline by Cardax Pharmaceuticals, Inc., H1 2014 80
Atherosclerosis - Pipeline by KineMed, Inc., H1 2014 81
Atherosclerosis - Pipeline by Bridge Bioresearch Plc, H1 2014 82
Atherosclerosis - Pipeline by ChemoCentryx, Inc., H1 2014 83
Atherosclerosis - Pipeline by Provid Pharmaceuticals, Inc., H1 2014 84
Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 85
Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2014 86
Atherosclerosis - Pipeline by NasVax Ltd., H1 2014 87
Atherosclerosis - Pipeline by Regulus Therapeutics Inc., H1 2014 88
Atherosclerosis - Pipeline by Janssen Biotech, Inc., H1 2014 89
Atherosclerosis - Pipeline by Esperion Therapeutics, Inc., H1 2014 90
Atherosclerosis - Pipeline by Vascular Pharmaceuticals, Inc., H1 2014 91
Atherosclerosis - Pipeline by SelectX Pharmaceuticals, Inc., H1 2014 92
Atherosclerosis - Pipeline by InVasc Therapeutics, Inc., H1 2014 93
Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 94
Atherosclerosis - Pipeline by DoNatur GmbH, H1 2014 95
Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H1 2014 96
Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H1 2014 97
Atherosclerosis - Pipeline by AtheroNova Inc., H1 2014 98
Atherosclerosis - Pipeline by Dybly AG, H1 2014 99
Atherosclerosis - Pipeline by vida therapeutics inc., H1 2014 100
Atherosclerosis - Pipeline by Biospherics.net Incorporated, H1 2014 101
Atherosclerosis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 102
Assessment by Monotherapy Products, H1 2014 103
Assessment by Combination Products, H1 2014 104
Number of Products by Stage and Target, H1 2014 107
Number of Products by Stage and Mechanism of Action, H1 2014 112
Number of Products by Stage and Route of Administration, H1 2014 116
Number of Products by Stage and Molecule Type, H1 2014 119
Atherosclerosis Therapeutics - Recent Pipeline Updates, H1 2014 265
Atherosclerosis - Dormant Projects, H1 2014 294
Atherosclerosis - Dormant Projects (Contd..1), H1 2014 295
Atherosclerosis - Dormant Projects (Contd..2), H1 2014 296
Atherosclerosis - Dormant Projects (Contd..3), H1 2014 297
Atherosclerosis - Dormant Projects (Contd..4), H1 2014 298
Atherosclerosis - Discontinued Products, H1 2014 299
List of Figures
Number of Products under Development for Atherosclerosis, H1 2014 21
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2014 22
Number of Products under Development by Companies, H1 2014 23
Number of Products under Investigation by Universities/Institutes, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 33
Comparative Analysis by Early Stage Products, H1 2014 34
Assessment by Monotherapy Products, H1 2014 103
Assessment by Combination Products, H1 2014 104
Number of Products by Top 10 Target, H1 2014 105
Number of Products by Stage and Top 10 Target, H1 2014 106
Number of Products by Top 10 Mechanism of Action, H1 2014 110
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 111
Number of Products by Top 10 Route of Administration, H1 2014 115
Number of Products by Stage and Top 10 Route of Administration, H1 2014 116
Number of Products by Top 10 Molecule Type, H1 2014 117
Number of Products by Stage and Top 10 Molecule Type, H1 2014 118
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Atherosclerosis Overview 12
Therapeutics Development 13
Pipeline Products for Atherosclerosis - Overview 13
Pipeline Products for Atherosclerosis - Comparative Analysis 14
Atherosclerosis - Therapeutics under Development by Companies 15
Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 21
Atherosclerosis - Pipeline Products Glance 24
Late Stage Products 24
Clinical Stage Products 25
Early Stage Products 26
Unknown Stage Products 27
Atherosclerosis - Products under Development by Companies 28
Atherosclerosis - Products under Investigation by Universities/Institutes 34
Atherosclerosis - Companies Involved in Therapeutics Development 36
Bristol-Myers Squibb Company 36
Aastrom Biosciences, Inc. 37
Johnson & Johnson 38
Boehringer Ingelheim GmbH 39
F. Hoffmann-La Roche Ltd. 40
AstraZeneca PLC 41
Eli Lilly and Company 42
GlaxoSmithKline plc 43
MedImmune, LLC 44
Isis Pharmaceuticals, Inc. 45
Daiichi Sankyo Company, Limited 46
Merck & Co., Inc. 47
Novartis AG 48
Dr. Reddy's Laboratories Limited 49
Kowa Company, Ltd. 50
The Medicines Company 51
Zydus Cadila Healthcare Limited 52
Bayer AG 53
OPKO Health, Inc. 54
Genfit SA 55
CSL Limited 56
Yuhan Corporation 57
Anagen Therapeutics, Inc. 58
Cytos Biotechnology AG 59
Resverlogix Corp. 60
Galapagos NV 61
Pronova BioPharma ASA 62
AFFiRiS AG 63
CIMAB S.A. 64
Jenrin Discovery, Inc. 65
Phenex Pharmaceuticals AG 66
Spherix Incorporated 67
Arisaph Pharmaceuticals, Inc. 68
Funxional Therapeutics Ltd 69
GenKyoTex S.A. 70
Vascular Biogenics Ltd. 71
Cardax Pharmaceuticals, Inc. 72
KineMed, Inc. 73
Bridge Bioresearch Plc 74
ChemoCentryx, Inc. 75
Provid Pharmaceuticals, Inc. 76
Vitae Pharmaceuticals, Inc. 77
Athera Biotechnologies AB 78
NasVax Ltd. 79
Regulus Therapeutics Inc. 80
Janssen Biotech, Inc. 81
Esperion Therapeutics, Inc. 82
Vascular Pharmaceuticals, Inc. 83
SelectX Pharmaceuticals, Inc. 84
InVasc Therapeutics, Inc. 85
Otsuka Holdings Co., Ltd. 86
DoNatur GmbH 87
Artery Therapeutics, Inc. 88
Lead Discovery Center GmbH 89
AtheroNova Inc. 90
Dybly AG 91
vida therapeutics inc. 92
Biospherics.net Incorporated 93
Dong-A Socio Holdings Co Ltd 94
Atherosclerosis - Therapeutics Assessment 95
Assessment by Monotherapy Products 95
Assessment by Combination Products 96
Assessment by Target 97
Assessment by Mechanism of Action 102
Assessment by Route of Administration 107
Assessment by Molecule Type 109
Drug Profiles 112
anacetrapib - Drug Profile 112
vorapaxar sulfate - Drug Profile 114
aliskiren fumarate - Drug Profile 116
evacetrapib - Drug Profile 118
DRL-17822 - Drug Profile 120
VB-201 - Drug Profile 121
RVX-208 - Drug Profile 123
CSL-112 - Drug Profile 125
chloroquine - Drug Profile 126
SYN-20110119RU - Drug Profile 127
XL-652 - Drug Profile 128
darapladib - Drug Profile 130
MDCO-216 - Drug Profile 132
ATH-03 - Drug Profile 134
AHRO-001 - Drug Profile 135
ISIS-APOARx - Drug Profile 137
(aspirin + clopidogrel) - Drug Profile 138
ACP-501 - Drug Profile 139
Vaccine for Atherosclerosis - Drug Profile 141
CVX-210H - Drug Profile 142
BI-691751 - Drug Profile 143
RO-6836191 - Drug Profile 144
LPC-01 - Drug Profile 145
Artpep-2 - Drug Profile 146
FX-141-L - Drug Profile 147
FX-87-L - Drug Profile 148
SOL-02 - Drug Profile 149
ixmyelocel-T - Drug Profile 150
SPX-7233801 - Drug Profile 153
ARI-1778 - Drug Profile 154
K-877 - Drug Profile 155
JD-2000 Series - Drug Profile 156
JD-5000 Series - Drug Profile 157
JD-6000 Series - Drug Profile 158
CYT018-IL1aQb - Drug Profile 159
AT-5261 - Drug Profile 160
GKT-137831 - Drug Profile 161
CDX-085 - Drug Profile 162
INV-404 - Drug Profile 164
INV-405 - Drug Profile 165
Drug For Atherosclerotic Plaque - Drug Profile 166
Annexin A-5 - Drug Profile 167
PC-mAb - Drug Profile 168
Anti-CD3 Oral Immunotherapy - Drug Profile 170
Protein-Based HDL Therapies - Drug Profile 172
Anti microRNA-33a/b - Drug Profile 174
(SPX-106 + D-tagatose) - Drug Profile 175
CD14 Project - Drug Profile 177
PRC-4016 - Drug Profile 178
Drug For Atherosclerosis - Drug Profile 179
YH_Chem3 - Drug Profile 180
KM-011 - Drug Profile 181
COR-2 - Drug Profile 182
CideB Antisense Oligonucleotide - Drug Profile 183
CCX-872 - Drug Profile 184
MCS-18 - Drug Profile 185
AEM-28 - Drug Profile 187
KRP-206 - Drug Profile 188
CCX-771 - Drug Profile 189
ketanserin - Drug Profile 190
Progranulin - Drug Profile 191
ARA-290 - Drug Profile 192
VTP-4 - Drug Profile 194
microRNA-145 Gene Therapy - Drug Profile 195
VPI-2690-B - Drug Profile 196
FX-5A - Drug Profile 197
Cell Migration Inhibitors - Drug Profile 198
ATI-829 - Drug Profile 199
GKT-136901 - Drug Profile 200
melittin - Drug Profile 202
GQ-16 - Drug Profile 203
BAY-606583 - Drug Profile 204
3-Hydroxyanthranilic Acid - Drug Profile 205
Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 206
VPI-2690-B - Drug Profile 207
Next Generation Lecinoxoids - Drug Profile 208
Bone Morphogenic Protein Inhibitors - Drug Profile 209
cSN-50 - Drug Profile 210
Atheroprotective Vaccine - Drug Profile 212
Small Molecules to Inhibit Chymase for Atherosclerosis - Drug Profile 213
DS-1442 - Drug Profile 214
Anti-CD20 Monoclonal Antibody - Drug Profile 215
RNAi Oligonucleotide to Inhibit STIM1 Cardiovascular Disorders - Drug Profile 216
DYB-186 - Drug Profile 217
Adenoviral Vector Based Human ABCG1 Gene Therapy - Drug Profile 218
AZ-876 - Drug Profile 219
Peptides Inhibiting Calcineurin - Drug Profile 220
Anti-CD97 Antibodies - Drug Profile 221
Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation - Drug Profile 222
Anti Idiotype chP3R99Q Vaccine - Drug Profile 223
AHRO-003 - Drug Profile 224
rPAI-123 - Drug Profile 225
BSN-723 - Drug Profile 226
BSN-272 - Drug Profile 227
K-312 - Drug Profile 228
D-4F - Drug Profile 229
EP-80317 - Drug Profile 230
Small Molecule to Inhibit CD40-TRAF6 Interaction for Atherosclerosis - Drug Profile 231
Biglycan Therapy - Drug Profile 232
PX-20606 - Drug Profile 233
CSN-501 - Drug Profile 234
CB-102 - Drug Profile 235
HDL AuNPs for Atherosclerosis and Lymphoma - Drug Profile 236
Lipase Inhibitors - Drug Profile 238
Small Molecules For Cardiovascular Disease - Drug Profile 239
Drug for Atherosclerosis - Drug Profile 240
Small Molecules for Atherosclerosis and Metabolic Diseases - Drug Profile 241
Drug Targeting F11R - Drug Profile 242
Stem Cell Therapy For Atherosclerosis - Drug Profile 244
Tanshinone IIA - Drug Profile 245
S-Allymercapto-N-Acetylcysteine - Drug Profile 246
Hepcidin Inhibitors - Drug Profile 247
Atherosclerosis Program - Drug Profile 248
Drug For Chronic Inflammatory Diseases - Drug Profile 249
Cannabinoid Receptor 2 Agonist - Drug Profile 250
Small Molecules to Inhibit Lipoxygenase for Oncology, Cardiovascular and Respiratory Disorders - Drug Profile 251
D-Amlexanox - Drug Profile 252
INV-88 - Drug Profile 253
dicumarol - Drug Profile 254
Nanotherapeutics - Drug Profile 255
AHRO-002 - Drug Profile 256
Atherosclerosis - Recent Pipeline Updates 257
Atherosclerosis - Dormant Projects 286
Atherosclerosis - Discontinued Products 291
Atherosclerosis - Product Development Milestones 292
Featured News & Press Releases 292
Appendix 301
Methodology 301
Coverage 301
Secondary Research 301
Primary Research 301
Expert Panel Validation 301
Contact Us 302
Disclaimer 302
List of Tables
Number of Products under Development for Atherosclerosis, H1 2014 21
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2014 22
Number of Products under Development by Companies, H1 2014 24
Number of Products under Development by Companies, H1 2014 (Contd..1) 25
Number of Products under Development by Companies, H1 2014 (Contd..2) 26
Number of Products under Development by Companies, H1 2014 (Contd..3) 27
Number of Products under Development by Companies, H1 2014 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H1 2014 30
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 31
Comparative Analysis by Late Stage Development, H1 2014 32
Comparative Analysis by Clinical Stage Development, H1 2014 33
Comparative Analysis by Early Stage Development, H1 2014 34
Comparative Analysis by Unknown Stage Development, H1 2014 35
Products under Development by Companies, H1 2014 36
Products under Development by Companies, H1 2014 (Contd..1) 37
Products under Development by Companies, H1 2014 (Contd..2) 38
Products under Development by Companies, H1 2014 (Contd..3) 39
Products under Development by Companies, H1 2014 (Contd..4) 40
Products under Development by Companies, H1 2014 (Contd..5) 41
Products under Investigation by Universities/Institutes, H1 2014 42
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 43
Atherosclerosis - Pipeline by Bristol-Myers Squibb Company, H1 2014 44
Atherosclerosis - Pipeline by Aastrom Biosciences, Inc., H1 2014 45
Atherosclerosis - Pipeline by Johnson & Johnson, H1 2014 46
Atherosclerosis - Pipeline by Boehringer Ingelheim GmbH, H1 2014 47
Atherosclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 48
Atherosclerosis - Pipeline by AstraZeneca PLC, H1 2014 49
Atherosclerosis - Pipeline by Eli Lilly and Company, H1 2014 50
Atherosclerosis - Pipeline by GlaxoSmithKline plc, H1 2014 51
Atherosclerosis - Pipeline by MedImmune, LLC, H1 2014 52
Atherosclerosis - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 53
Atherosclerosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 54
Atherosclerosis - Pipeline by Merck & Co., Inc., H1 2014 55
Atherosclerosis - Pipeline by Novartis AG, H1 2014 56
Atherosclerosis - Pipeline by Dr. Reddy's Laboratories Limited, H1 2014 57
Atherosclerosis - Pipeline by Kowa Company, Ltd., H1 2014 58
Atherosclerosis - Pipeline by The Medicines Company, H1 2014 59
Atherosclerosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 60
Atherosclerosis - Pipeline by Bayer AG, H1 2014 61
Atherosclerosis - Pipeline by OPKO Health, Inc., H1 2014 62
Atherosclerosis - Pipeline by Genfit SA, H1 2014 63
Atherosclerosis - Pipeline by CSL Limited, H1 2014 64
Atherosclerosis - Pipeline by Yuhan Corporation, H1 2014 65
Atherosclerosis - Pipeline by Anagen Therapeutics, Inc., H1 2014 66
Atherosclerosis - Pipeline by Cytos Biotechnology AG, H1 2014 67
Atherosclerosis - Pipeline by Resverlogix Corp., H1 2014 68
Atherosclerosis - Pipeline by Galapagos NV, H1 2014 69
Atherosclerosis - Pipeline by Pronova BioPharma ASA, H1 2014 70
Atherosclerosis - Pipeline by AFFiRiS AG, H1 2014 71
Atherosclerosis - Pipeline by CIMAB S.A., H1 2014 72
Atherosclerosis - Pipeline by Jenrin Discovery, Inc., H1 2014 73
Atherosclerosis - Pipeline by Phenex Pharmaceuticals AG, H1 2014 74
Atherosclerosis - Pipeline by Spherix Incorporated, H1 2014 75
Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2014 76
Atherosclerosis - Pipeline by Funxional Therapeutics Ltd, H1 2014 77
Atherosclerosis - Pipeline by GenKyoTex S.A., H1 2014 78
Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H1 2014 79
Atherosclerosis - Pipeline by Cardax Pharmaceuticals, Inc., H1 2014 80
Atherosclerosis - Pipeline by KineMed, Inc., H1 2014 81
Atherosclerosis - Pipeline by Bridge Bioresearch Plc, H1 2014 82
Atherosclerosis - Pipeline by ChemoCentryx, Inc., H1 2014 83
Atherosclerosis - Pipeline by Provid Pharmaceuticals, Inc., H1 2014 84
Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 85
Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2014 86
Atherosclerosis - Pipeline by NasVax Ltd., H1 2014 87
Atherosclerosis - Pipeline by Regulus Therapeutics Inc., H1 2014 88
Atherosclerosis - Pipeline by Janssen Biotech, Inc., H1 2014 89
Atherosclerosis - Pipeline by Esperion Therapeutics, Inc., H1 2014 90
Atherosclerosis - Pipeline by Vascular Pharmaceuticals, Inc., H1 2014 91
Atherosclerosis - Pipeline by SelectX Pharmaceuticals, Inc., H1 2014 92
Atherosclerosis - Pipeline by InVasc Therapeutics, Inc., H1 2014 93
Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 94
Atherosclerosis - Pipeline by DoNatur GmbH, H1 2014 95
Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H1 2014 96
Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H1 2014 97
Atherosclerosis - Pipeline by AtheroNova Inc., H1 2014 98
Atherosclerosis - Pipeline by Dybly AG, H1 2014 99
Atherosclerosis - Pipeline by vida therapeutics inc., H1 2014 100
Atherosclerosis - Pipeline by Biospherics.net Incorporated, H1 2014 101
Atherosclerosis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 102
Assessment by Monotherapy Products, H1 2014 103
Assessment by Combination Products, H1 2014 104
Number of Products by Stage and Target, H1 2014 107
Number of Products by Stage and Mechanism of Action, H1 2014 112
Number of Products by Stage and Route of Administration, H1 2014 116
Number of Products by Stage and Molecule Type, H1 2014 119
Atherosclerosis Therapeutics - Recent Pipeline Updates, H1 2014 265
Atherosclerosis - Dormant Projects, H1 2014 294
Atherosclerosis - Dormant Projects (Contd..1), H1 2014 295
Atherosclerosis - Dormant Projects (Contd..2), H1 2014 296
Atherosclerosis - Dormant Projects (Contd..3), H1 2014 297
Atherosclerosis - Dormant Projects (Contd..4), H1 2014 298
Atherosclerosis - Discontinued Products, H1 2014 299
List of Figures
Number of Products under Development for Atherosclerosis, H1 2014 21
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2014 22
Number of Products under Development by Companies, H1 2014 23
Number of Products under Investigation by Universities/Institutes, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 33
Comparative Analysis by Early Stage Products, H1 2014 34
Assessment by Monotherapy Products, H1 2014 103
Assessment by Combination Products, H1 2014 104
Number of Products by Top 10 Target, H1 2014 105
Number of Products by Stage and Top 10 Target, H1 2014 106
Number of Products by Top 10 Mechanism of Action, H1 2014 110
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 111
Number of Products by Top 10 Route of Administration, H1 2014 115
Number of Products by Stage and Top 10 Route of Administration, H1 2014 116
Number of Products by Top 10 Molecule Type, H1 2014 117
Number of Products by Stage and Top 10 Molecule Type, H1 2014 118
